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ABSTRACT 
 
Objective 
 
Several studies have shown that serum copper concentrations are higher in various 
carcinomas when compared to a healthy population; owing to their role as an inflammatory 
marker. Zinc acts as a cellular growth protector and it has been demonstrated that its 
deficiency is involved in several stages of malignant cell transformation. However, the 
usefulness of the serum zinc and copper determinations in cancer prevention, detection, 
treatment monitoring and prognosis require further investigation.  
 
The aim of this study is to demonstrate the diagnostic and prognostic significance of serum 
zinc levels (SZL) and serum copper levels (SCL), and the copper/zinc (Cu/Zn) ratio, in non-
small cell lung cancer (NSCLC). 
 
Materials and Methods 
 
Thirty-four patients with NSCLC were prospectively identified, prior to treatment, over a 
period of one calendar year (February 2003 - January 2004) at the Department of Radiation 
Oncology, Johannesburg General Hospital (now Charlotte Maxeke Johannesburg Academic 
Hospital) and the University of the Witwatersrand. SCL and SZL were measured using 
atomic absorption spectroscopy (AAS) and the Cu/Zn ratio was calculated. 
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Results 
 
SCL shows an increase (mean SCL were 0.66mg/L, 0.74mg/L and 0.76mg/L for stage II, III 
and IV respectively) (P=0.0897); and SZL shows a decrease (0.70mg/L,0.63mg/L and 
0.62mg/L for stage II, III and IV respectively) (P=0.199)  with advancing stage. The levels of 
both these trace elements are much lower than the reference range for a normal population. 
The Cu/Zn ratio increases with stage (0.995, 1.308 and 1.441 for stage II, III and IV 
respectively). The results were not statistically significant, but a definite trend could be 
observed. In addition, marked differences were noted between early stages (II) and advanced 
stages (III and IV) of the disease. 
 
Conclusion 
 
The lower levels of both trace elements, when compared to a reference range, are an  
indication of the low levels of immunity and poor general condition of patients with  
NSCLC (with particular reference to the author‟s institution).  A clear trend could be 
 demonstrated of increasing SCLs and decreasing SZLs with progressive stages in NSCLC. 
The Cu/Zn ratio also reflects similar findings in relation to stages of the disease. 
 
The results were not statistically significant, although this can be attributed to a small sample 
size.  While trace element levels and the Cu/Zn ratio cannot be advocated as a tumour marker 
and prognostic variable for NSCLC at present, they do merit further study, especially in a 
resource constrained environment, as a simple and inexpensive diagnostic and prognostic 
test. 
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DEFINITION OF TERMS 
 
Performance Status 
 
In the clinical discipline of oncology, two main classifications are used in the assessment of a 
patient‟s general physical and functional condition, viz.: 
 
1)  Eastern Co-operative Group (ECOG) Staging (a simple grading system of 
functional status from 0-5). 
0 Asymptomatic  
(Fully active, able to carry on all pre-disease activities without restriction.) 
1 Symptomatic but completely ambulatory  
(Restricted in physically strenuous activity but ambulatory and able to   
carry out work of a light or sedentary nature. For example, light office          
work). 
2 Symptomatic, <50% in bed during the day  
 (Ambulatory and capable of all self-care but unable to carry out any                                                  
work activities. Up and about more than 50% of waking hours.)  
3 Symptomatic, >50% in bed, but not bedbound  
 (Capable of only limited self-care, confined to a bed or chair 50% or                                     
more of waking hours.) 
4  Bedbound  
(Completely disabled. Unable to carry out any self-care. Totally confined to a 
bed or chair.) 
5 Death 
 
 (Also known as the WHO scoring.) 
 
This can be summarized as 0-2 being good general condition and probably suitable for radical 
treatment; and 3-4 being poor general condition and probably suitable for palliative 
treatment. 
 
 
x 
 
2) Karnofsky Scoring - a more extensive scoring system (from 100 - 0)  
               
  100%  normal, no complaints, no signs of disease 
90%  capable of normal activity, few symptoms or signs of disease 
80%  normal activity with some difficulty, some symptoms or signs         
70%  caring for self, not capable of normal activity or work   
60%  requiring some help, can take care of most personal requirements 
50%  requires help often, requires frequent medical care 
40%  disabled, requires special care and help 
30%  severely disabled, hospital admission indicated but no risk of death 
20%  very ill, urgently requiring admission, requires supportive measures or 
treatment 
10%  moribund, rapidly progressive fatal disease processes 
0%      Death 
           
Early Stage and Advanced Disease 
 
The general clinical opinion in oncology (NCCN level 1 consensus) with regard to NSCLC is 
that Stage I & II of the disease (AJCC 2002) be viewed as early stage, and Stage III & IV as 
advanced disease stage (in terms of clinical decision making). 
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LIST OF ACRONYMS AND ABBREVIATIONS 
 
AAS: Atomic absorption spectroscopy 
AJCC: American Joint Committee on Cancer 
CT: Computerized tomography  
NHLS: National Health Laboratory Services 
NSCLC: Non-small cell lung cancer 
QC: Quality control  
SCLC: Small cell lung cancer 
 SZL:              Serum zinc levels 
SCL:              Serum copper levels 
ECOG:        Eastern Co-operative Oncology Group 
NCCN:         National Comprehensive Cancer Network 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
 
 
Lung cancer accounts for 18% of deaths from cancer, making it the cancer with the 
highest mortality rate in the world, in both men and women.
1
  
 
Cigarette smoking increases the risk of getting lung cancer and dying from it, with 
approximately 80% of cases caused by smoking.
2
 Other causes of lung cancer are 
genetic factors
3
, exposure to asbestos
4
, atmospheric pollution and passive smoke 
inhalation .
5, 6, 7
  
 
Lung carcinogenesis is known to occur from an accumulation of several genetic 
alterations, most commonly with p53 mutations and deletions on chromosomes 3p, 5q, 
9p, 11p and 17p.
8
 These alterations are more frequently seen in smokers than in non-
smokers
8
 and peak incidence occurs in the 7th and 8th decades. 
 
Changes in smoking prevalence and patterns have produced changes in the incidence of 
lung cancer globally. While there is a substantial decline in the incidence of lung cancer 
in the developed world
,9 
 a rise in incidence is noticed in the populations of developing 
countries and among women.
10, 11
 Socio-economic factors and level of education (both 
individual and awareness campaigns) show a strong correlation with lung cancer 
incidence and prevalence. 
 
Lung cancer can be categorised histologically into two groups, viz.: small cell lung 
cancer (SCLC); and non-small cell lung cancer (NSCLC). SCLC is usually 
2 
 
disseminated at presentation, owing to its predisposition to early metastatic spread, thus 
conferring a poorer prognosis. SCLC is almost always associated with smoking, though 
its aetiology and pathophysiology are much less clear.
12 
 
Treatment of lung cancer is dependent on cell type, stage of the disease and the patient‟s 
performance status.  Small cell lung cancer (SCLC) is usually considered a systemic 
disease at the time of diagnosis, owing to its propensity for widespread haematogenous 
spread (more than 75% of patients with SCLC present with metastatic disease). 
Associated paraneoplastic syndromes include: the syndrome of inappropriate 
antidiuretic hormone (SIADH), most commonly, hypercoaguable states (common); 
ectopic adrenocorticotropic hormone (ACTH) syndrome (uncommon); and Eaton-
Lambert (myasthenia) syndrome (rarely seen with any other tumour). Hypercalcaemia 
occurs rarely in SCLC, even in the presence of extensive bony metastases. 
 
 SCLC is chemo-sensitive, which makes chemotherapy the most appropriate first line 
treatment. Radiotherapy may also be administered, usually as a palliative treatment,
13, 14 
 
or for prophylactic brain irradiation in selected cases. Relapse almost always occurs in 
SCLC in sites previously affected, as well as in previously uninvolved ones, after both 
chemotherapy and radiotherapy.   
 
Non-small cell lung cancer (NSCLC) accounts for by far the majority of cases of lung 
cancer worldwide (80% - 85%). The histological variants (squamous, adenocarcinoma, 
large cell) are grouped together as NSCLC because of similarities in presentation, 
treatment and natural history.  
 
3 
 
Squamous cell carcinoma (20% - 25% of NSCLC) was previously thought to occur in a 
predominantly central location, whereas adenocarcinoma occurred peripherally. Recent 
studies show a changing radiographic presentation, with the two cell types having 
similar patterns of presentation.
15
 Compared with other kinds of lung cancers, squamous 
cell lung cancers are most likely to remain localised early in the disease and to recur 
locally after surgery or radiotherapy.  
 
Hypercalcaemia, resulting from ectopic production of parathyroid hormone-related 
peptide (PTH–RP), is the most frequent associated paraneoplastic syndrome. 
Hypertrophic osteoarthropathy (occasional), paraneoplastic neutrophilia (sometimes 
associated with hypercalaemia), prominent joint syndromes (occasional), or 
hypercoagulability are also seen.  
 
While adenocarcinoma is the most commonly associated sub-type in both non-smokers 
and women, most cases are related to smoking. More than half of all patients with 
adenocarcinoma initially localised as a peripheral nodule, have regional nodal 
metastases.
15 
Adenocarcinoma, and large cell carcinomas have similar natural histories 
and spread widely outside the thorax by haematogenous dissemination, commonly 
involving the bones, liver and brain.
15
 Associated paraneoplastic syndromes include: 
hypertrophic osteoarthropathy, hypercoaguable states, hypercalcaemia due to PTH–RP 
or cytokines, and gynaecomastia (large cell). 
  
Although surgical excision offers the best prospect of cure for NSCLC, only about 20% 
of patients present at a resectable stage.
16
This figure is probably lower in a South 
4 
 
African context. For NSCLC patients who are not eligible for surgery, radiotherapy or 
chemo-radiotherapy is the most appropriate treatment option .
14, 17 
 
Survival outcome with lung cancer is one of the lowest when compared to other solid 
tumour cancers; this is largely due to late diagnosis in the majority of the patients, when 
curative treatment is no longer possible.
14, 17  
The reasons for these dismal statistics are 
essentially two-fold, viz.: lack of a cost-effective screening technique (with consequent 
late stage at presentation); and sub-optimal treatment for advanced stage disease. Both 
prevalence and survival have been correlated with socio-economic factors .
10, 11  
 
Five year survival estimates in the USA, are 13% for men and 17% for women 
(overall). In the UK it is 7.4 % and 7.9% for men and women respectively.
18, 19, 20
 Lung 
cancer survival is related to stage at presentation, with survival declining at higher 
stages of malignancy. Five year survival rates for NSCLC for respective stages at 
presentation are:  
 stage IIa : 36% - 46% 
 stage IIb : 25% - 36% 
 stage IIIa : 19% - 24% 
 stage IIIb : 7% - 9% 
 stage IV : 2 % - 13%
18
   
 
There is a paucity of accurate statistics in the developing world, but consensus of 
opinion and crude statistics suggest that patients in a middle income developing country 
like South Africa would have a higher stage at presentation and a lower survival rate by 
stage when compared to patients in the USA .
11, 12 
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Trace elements are known to play a vital role in many biological processes by their 
action as competitors with other elements and proteins for binding sites (competitive 
inhibition). They also serve as molecular activators and inhibitors and in other processes 
of cell regulation.
21, 22 
 
The biological role of trace metals, especially of copper and zinc, in different 
physiologic and pathological conditions has been the subject of many studies over the 
past two to three decades. Interest in the study of serum levels of trace elements has 
increased recently owing to research findings that suggest that these elements could be 
of value in the diagnosis, staging and monitoring of malignancies.
20, 23, 24
 In essence, the 
levels of these elements in serum, and their ratio to one another, could be used as a 
tumour marker.
25 
Further impetus to this possible use has been added by the probability 
of reduced laboratory and other costs associated with testing, owing to advanced 
technology. 
 
Zinc is an essential trace element in humans and is constituent of many enzymes. It is 
involved in many metabolic pathways and acts as a co-enzyme and a cellular growth 
protector. It plays an important role in nucleic acid metabolism, cell replication, tissue 
repair and growth through its function as a nucleic acid polymerase. It is essential for 
the synthesis of RNA and DNA.
26
 Serum zinc levels (SZL) are shown to decline in 
malignant disease and its deficiency has been demonstrated to be involved in several 
stages of malignant disease progression
27-29
, with the level declining with advancing 
disease stages.
26, 30-35
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Zinc, along with copper, represents a vital cog in the machinery of the cell.
36-40 
Zinc is 
an important component of enzymes, principally oxidases, and is associated with 
immune suppression, probably as a result of altered absorption. Through the 
stabilization of the structure of deoxyribonucleic acid (DNA), ribonucleic (RNA) and 
ribosome, zinc plays an anticarcinogenic role 
41
, by also protecting cells from free-
radical injury.
42 
 
Clinical manifestations of zinc deficiency include growth retardation, retarded skeletal 
maturation, testicular atrophy and increased susceptibility to infections. The association 
of a zinc deficiency with malignancy is not clearly understood
41
, even though zinc 
deficiency is associated with advanced malignancy.
43-46 
Recently, emphasis has been 
placed on the study of tumour markers in human cancer. 
46–50 
Disease perturbation of the 
homeostasis of serum concentrations of trace elements has been demonstrated to be a 
useful adjunct to diagnosis, as well as prognosis in specific diseases.
46-50 
 
Copper is an essential trace element that is widely distributed in food and water. Copper 
is a component of metalloenzymes such as ceruloplasmin, cytochrome oxidase, 
dopamine hydroxylase and tyrosinase.
35
 Ceruloplasmin, which carries 96% of total 
serum copper, is responsible for oxidizing DOPA, dopamine, adrenaline, noradrenaline 
and serotonin.
36 
In the extracellular space, ionised copper induces the synthesis of 
adhesive fibronectin and collagen, which stimulates the migration of neoplastic cells.
37, 
38
 In addition, ionized copper binds with heparin and fibroblast growth factor, an 
angiogenic protein that is also involved in cell migration.
39 
Copper plays a key role in 
the absorption and metabolism of iron.
40 
Copper deficiency states are rare and may 
7 
 
manifest clinically as anaemia or pancytopaenia and, very rarely, as a neurodegenerative 
disorder. 
 
Copper is found in a variety of enzymes and is closely related with haematopoiesis and 
the metabolism of osseous and connective tissue.
27
 Copper has also been shown to be a 
vital angiogenic co-factor.
27, 28
 Serum copper levels (SCL) can be interpreted as an acute 
phase protein that increases in malignancy and in other causes of inflammation. 
Increases of SCL in malignant disease are shown to be much higher than in benign 
disease. 
29 
 
Previous reports have shown abnormal serum levels of zinc and copper in a number of 
malignancies, including lung cancer
25, 29
, brain tumours
30
 and ovarian cancer.
31
 
However, contradictory data exist on the usefulness of copper and zinc measurements in 
the diagnosis and prognosis of cancer.
25-31
 Furthermore, the ratio of serum copper to 
zinc has been shown to be a more reliable and accurate parameter for prognosis than 
individual serum copper or serum zinc levels (SZL). There is a trend to higher ratios in 
more advanced disease.
32 
 
This study aimed to investigate the use of serum levels of copper (SCL), SZL and the 
serum copper to zinc (Cu/Zn) ratio as a diagnostic and prognostic tool as well as a 
possible tumour marker in NSCLC in the South African population. 
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CHAPTER TWO: AIM and OBJECTIVES 
 
 
AIM  
 
To assess the feasibility of biochemical parameters as a cost-effective staging and 
prognostic tool in non-small cell lung cancer (NSCLC), with specific reference to a 
developmental setting. 
 
SPECIFIC STUDY OBJECTIVES 
 
The objective of this study is to analyse pre-treatment levels of serum zinc (SZL) and 
copper (SCL) in NSCLC and to correlate these levels, as well as the Cu/Zn ratio, to help 
ascertain their diagnostic and prognostic value with regard to:  
 diagnosis of NSCLC 
 disease progression and stage, and thus usefulness as a prognostic variable 
 use as a tumour marker 
 
  
  
9 
 
CHAPTER 3: METHODOLOGY 
 
 
 This is a prospective cohort study, which was done at the Radiation Oncology 
Department of the Johannesburg General Hospital [now Charlotte Maxeke 
Johannesburg Academic Hospital]. Recruitment of participants was done at the 
Charlotte Maxeke Johannesburg Academic Hospital over a one-year period from 
February 1, 2003 to January 31, 2004. 
 
 
Inclusion criteria were:  
 
 Study participants were patients with NSCLC.  
 Eligible patients had a cytological or histological confirmation of NSCLC 
 All patients who volunteered to participate in this study were 18 years or older. 
 All participants signed an Informed Consent Form (see Appendix 3).  
 All the study participants were HIV negative at the time of enrolment. 
 
Exclusion criteria were: 
 
    Participants taking trace element and/or vitamin supplements, or with diseases 
of malabsorption. 
    HIV infected patients. 
 
 
10 
 
NB:  
Age, general condition and performance status (ECOG and Karnofsky Performance 
Status scale ratings) were NOT used as inclusion or exclusion criteria. 
Participants were included in the study prior to treatment and their management was not 
affected in any way. 
 
Cytological and histological diagnosis of NSCLC was carried out by the National 
Health Laboratory Services (NHLS). Histological sub-types of NSCLC viz. squamous 
cell lung cancer, adenocarcinoma and large cell carcinoma were specified. 
 
Participants were counselled by a professional nurse. No financial incentives were 
offered and participation or refusal in the trial did not affect the medical management of 
participants. 
 
All patients in the Department of Radiation Oncology have a known HIV status. HIV 
Elisa testing upon diagnosis of malignancy was standard departmental protocol during 
the period of the study.  HIV infected patients were excluded, owing to the unknown 
effect of the infection on trace element absorption and secretion. To ensure accuracy in 
the serum levels of zinc and copper, patients taking trace element and/or vitamin 
supplements, or with diseases of malabsorption, were excluded. 
 
Atomic absorption spectroscopy (AAS) was employed in measuring serum levels of 
copper and zinc.
33
  
 
 
11 
 
3.1  Sample Size  
 
Thirty-four (34) newly diagnosed, histologically or cytologically proven patients with 
NSCLC were prospectively included in the study. The study group comprised twenty-
five (25) males and nine (9) females. 
 
Owing to funding and logistic constraints, patient inclusion was limited to patients 
presenting at the Department of Radiation Oncology, Charlotte Maxeke Johannesburg 
Academic Hospital over a period of one calendar year.  
 
None of the patients had undergone chemotherapy or radiotherapy before the 
commencement of the study.  
 
Patients were staged according to the departmental protocol at the time.  Cancer stage 
was established based on the results of routine investigations done at the department, 
viz.: chest x-rays, CT scans of the chest and abdomen, and/or bronchoscopy and  
mediastinoscopy.  Bone scans were done when indicated, depending on the symptoms 
of the patients.  The patients were staged according to the American Joint Committee on 
Cancer (AJCC) 2002 classification. Standard laboratory tests for lung cancer were also 
performed. 
 
There were no patients with stage I of the disease. The studied patients were grouped 
into 3 stages, i.e. stages II to IV.  
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3.2   Blood Sample Collection and Measurement 
 
Patients‟ blood samples were obtained by venepuncture to avoid external contamination 
and haemolysis. The blood was centrifuged and serum frozen until analysis. Blood 
sample collection was done by trained and registered phlebotomists at the Charlotte 
Maxeke Johannesburg Academic Hospital.  
 
3.3  Sample Analysis and Measurement 
 
The determination of serum levels of copper and zinc was carried out using AAS. AAS 
is a method of determining the concentration of a particular metal constituent in a 
sample. AAS uses the absorption of light to measure the concentration of gas-phase 
atoms.  
 
The AAS process involves two major steps, i.e.:  
A)   Atomisation of the sample: Samples in liquid or solid form are vaporized to covert 
atoms into a free state by exposing the sample to a flame. This converts the 
analysed sample into a form that can be measured. Atomisation involves the 
following steps: 
 Desolvation: the liquid solvent is evaporated and the dry sample remains. 
 Vaporisation: the solid vaporises to a gas. 
 Atomisation.  
 The compounds making up the sample are broken up into free atoms. 
B)   Absorption: The atoms in their free state are then exposed to light of appropriate 
wavelength, which causes the atoms to transition to higher electronic energy  
13 
 
levels. The greater the number of atoms there is in the vapour, the greater is the amount 
of radiation is absorbed. The amount of light absorbed is proportional to the number of 
atoms. 
 
The analyte concentration is determined from the amount of light absorption, which is 
measured against a standard curve. A standard curve is constructed by running several 
samples of known metal concentration under the same conditions as used when running 
the unknown metal. The amount of the known absorption is compared with the standard 
curve and this enables the calculation of the unknown concentration in a sample. 
 
Due to the unique configuration of electrons in its outer shell, every atom has its own 
distinct pattern of wavelength at which it will absorb energy. The wavelength absorbed 
corresponds to the energy needed to promote electrons from one energy level to another, 
higher, energy level. 
 
In order to measure elements using the AAS technique, an atomic absorption 
spectrometer with the following components: a light source; a sample cell to produce 
gaseous atoms; and a means of measuring the specific light absorbed. 
 
The light source 
 
The source of light is a „hollow cathode lamp‟, which contains a tungsten anode, and a 
cylindrical hollow cathode made of the element to be determined. These are sealed in a 
glass tube filled with an inert gas, such as neon or argon.  
 
14 
 
By applying a potential difference of about 300–400V between the anode and the 
cathode, ionization of atoms takes place. These gaseous ions bombard the cathode and 
eject metal atoms from the cathode in a process called sputtering. Some sputtered atoms 
are in an excited state and emit radiation characteristic of the metal as they fall back to 
the ground state. The shape of the cathode concentrates the radiation into a beam, which 
passes through a quartz window, and the shape of the lamp is such that most of the 
sputtered atoms are re-deposited on the cathode. 
 
The atomic absorption instrument holds several lamps, each for a different element. 
These lamps are housed in a rotating turret so that the correct lamp can be selected 
quickly. 
 
The optical system and detector 
 
A monochromator is used to select the specific wavelength of light – the spectral line – 
that is absorbed by the sample and to exclude other wavelengths. The selection of the 
specific light allows the determination of the selected element in the presence of others. 
The light selected by the monochromator is directed onto a detector (typically a 
photomultiplier tube). This produces an electrical signal proportional to the light 
intensity. 
 
Double beam spectrometers 
 
Modern spectrometers incorporate a beam splitter so that one part of the beam passes 
through the sample cell and the other is the reference. The intensity of the light source 
15 
 
may not stay constant during an analysis. If only a single beam is used to pass through 
the atom cell, a blank reading containing no analyte (substance to be analysed) would 
have to be taken first, setting the absorbance at zero. If the intensity of the source 
changes by the time the sample is put in place, the measurement will be inaccurate.  
 
In the double beam instrument, there is constant monitoring between the reference beam 
and the light source. To ensure that the spectrum does not suffer from loss of sensitivity, 
the beam splitter is designed so that as high a proportion of the energy of the lamp beam 
as possible passes through the sample. 
 
Atomisation of the sample 
 
Two systems are commonly used to produce atoms from the sample, i.e.: 
            - Aspiration: this involves sucking a solution of the sample into a flame. 
- Electro-thermal atomisation: drop of sample is placed into a graphite tube 
 that is then heated electrically.  
 
The aspiration technique was employed in this study. 
 
Background absorption 
 
It is possible that other atoms or molecules, apart from those of the element being 
determined, will absorb or scatter some radiation from the light source. These species 
could include unvaporised solvent droplets, or compounds of the matrix (chemical 
species, such as anions, which tend to accompany the metals being analysed) that are 
16 
 
not removed completely. This means that there is background absorption as well as 
absorption by the sample. One way of measuring and correcting this background 
absorption is to use two light sources, one of which is the hollow cathode lamp 
appropriate to the element being measured. The second light source is a deuterium 
lamp. 
 
The deuterium lamp produces broad band radiation, not specific spectral lines as with a 
hollow cathode lamp. By alternating the measurements of the two light sources – 
generally at 50 –100 Hz – the total absorption (absorption due to analyte atoms plus 
background) is measured with the specific light from the hollow cathode lamp and the 
background absorption is measured with the light from the deuterium lamp. Subtracting 
the background from the total absorption gives the absorption arising from only 
analyte atoms. 
 
Calibration 
 
A calibration curve is used to determine the unknown concentration of an element in a 
solution. The instrument is calibrated using several solutions of known concentrations.  
A calibration curve is produced that is continually re-scaled as more concentrated 
solutions are used – the more concentrated solutions absorb more radiation up to a 
certain absorbance level. The calibration curve shows the concentration against the 
amount of radiation absorbed. 
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The sample solution is fed into the instrument and the unknown concentration of the 
element is then displayed on the calibration curve. In this study, zinc and copper were 
studied. 
 
The use of special light sources and specific wavelength selection allows the 
quantitative determination of individual components of a multi-element mixture.
33, 34
  
 
3.4)  Measurement of Copper 
 
Principle: 
Diluted serum samples are aspirated into a flame. The atoms at ground state absorb 
incident light emanating from a copper hollow cathode lamp at the resonance 
wavelength of 324.8nm. Absorbance of energy at this wavelength is specific for copper 
and proportional to its concentration. 
 
Specimen: 
A fresh 5ml sample of clotted blood was collected into a plastic-topped tube. The use of 
rubber stoppers was avoided, as these stoppers may affect the results. 
 
Materials and equipment: 
1.  Atomic absorption spectrophotometer 
2.  Assorted pipettes 
3.  A copper hollow cathode lamp - Varian Cat No. 56-101233-00 
4.  BDH Spectrosol 1000mg/l copper solution_BDH Cat No. 141392N 
5.  Glycerol-Merck Cat No. 104092 
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6.  Milli-Q water 
7.  Sterile disposable urine containers 
8.  500ml volumetric flask 
 
All glassware was washed by soaking the glassware in 6N nitric acid overnight; it was 
rinsed using Milli-Q water. All reagents were transferred to a plastic container 
immediately after preparation. 
 
Reagents: 
1. Sample and 50ml of standard diluent 10% glycerol was measured into a 500ml 
volumetric flask. 
2. Water was added to make up volume to 500ml. 
 
Calibration: 
1. Stock standard-BDH spectrosol 1000mg/l copper solution. 
2. Intermediate stock standard - 1000μmol/L transferred into a universal container 
(plastic urine bottle). 14.7ml of Milli-Q water was added using a pipette. 1000μl 
of stock copper solution was then added. 
3. Working standards - The following was measured out into four urine containers: 
Copper concentration gm of water μl of standard 
5.00 19.90 100 
10.00 19.80 200 
20.00 19.60 400 
40.00 19.20 800 
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Quality Control (QC) 
 
Internal QC: 
1. Bio Rad QCS 2 was used as control 1 and Humatrol P as control 2 for accuracy 
controls. 
2. The sample was reconstituted with 5ml Milli-Q water and allowed to stand for 30 
minutes. The results of QC were recorded. 
 
Procedure - Stepwise: 
1. The atomic absorption spectrophotometer is switched on. 
2. Set to wavelength  - 324.8nm 
Lamp current   - 5 
Acetylene  - 19-22 
Slit width  - 0.5 
Program   - 4 
Air flow   - 35 
3. Allow lamp to warm up for 30 minutes. 
4. Light flame and aspirate using Milli-Q water. 
 
Method: 
1. Diluted all standards as follows: 1.0ml standard + 1.0ml glycerol 
2. Diluted all serum samples and controls: 0.5ml serum + 0.5ml water 
3. Standards were aspirated and calibrated. 
4. After calibration, samples and controls were run on the instrument using water as 
a blank between each sample. 
20 
 
5. Results were taken from the printout. 
 
3.5)  Measurement of Zinc 
 
Principle: 
Diluted serum samples are aspirated into a flame. The atoms at ground state absorb 
incident light emanating from a zinc hollow cathode lamp at the resonance wavelength 
of 213.9nm. Absorbance of energy at this wavelength is specific for zinc and 
proportional to its concentration. 
 
Specimen: 
5ml of fresh blood was collected pre-prandial into a plastic topped tube. This was 
because zinc levels may fall by 20% after meals. The use of rubber stoppers was 
avoided because these affect the results markedly. 
 
Materials and equipment: 
1. Atomic absorption spectrophotometer 
2. Assorted pipettes 
3. A zinc hollow cathode lamp - Varian Cat No. 56-101-00 
4. BDH Spectrosol 1000mg/l zinc solution 
5.  Glycerol-Merck  
6. Milli-Q water 
7. Sterile disposable urine containers 
8. 500ml volumetric flask 
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All glassware was washed by soaking it in 6N nitric acid overnight. It was rinsed using 
Milli-Q water. All reagents were transferred to a plastic container immediately after 
preparation. 
 
Reagents: 
1. The sample and 50ml of standard diluent 10% glycerol was measured into a 
500ml volumetric flask. 
2. Water was added to make up volume to 500ml. 
 
Calibration: 
1. Stock standard - BDH spectrosol 1000mg/l zinc solution 
2. Intermediate stock standard - 1000μmol/L 
3. A universal container (plastic urine bottle) was used and 14.3ml of Milli-Q water 
was added using a pipette. 
4. 1000μl of stock zinc solution was then added. 
5. Working standards - The following was measured out into four urine containers: 
Zinc concentration gm of water μl of standard 
5.00 19.90 100 
10.00 19.80 200 
20.00 19.60 400 
40.00 19.20 800 
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Quality Control (QC) 
 
Internal QC: 
1. Serosods and Serosods plus were used for accuracy controls. 
2. The sample was reconstituted with 5ml Milli-Q water and allowed to stand for 30 
minutes. The results of QC were recorded. 
 
Procedure-Stepwise: 
1. The atomic absorption spectrophotometer is switched on. 
2. Set to wavelength   – 213.9nm 
Lamp current  - 10 
Acetylene  - 19-22 
Slit width  - 0.5 
Program  - 4 
Air flow  - 35 
3. Allow lamp to warm up for 30 minutes. 
4. Light flame and aspirate using Milli-Q water. 
 
Method: 
1. Diluted all standards as follows: 1.0ml standard + 1.0ml glycerol. 
2. Diluted all serum samples and controls: 0.5ml serum + 0.5ml water. 
3. Standards were aspirated and calibrated. 
4. After calibration, samples and controls were run on the instrument using water as a 
blank between each sample. 
5. Results were taken from the printout. 
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AAS is a technique that has been found to be reliable and valid for routine analysis of 
patient sample serum zinc.
28 
 
Serum analysis of zinc and copper for this study was done at the National Atomic 
Centre (NAC) Laboratory, Witwatersrand branch (Now iTemba Labs). iTemba is an 
academic laboratory affiliated to the University of the Witwatersrand. It is accredited to 
carry out serum analysis of zinc, copper and molybdenum using the AAS technique. 
 
 
3.6   Data Analysis 
 
The study is a prospective trial with three groups of participants divided according to 
stage (II-IV). In order to describe the demographic characteristics of the patients,  
frequency, means and standard deviations were used. 
 
Normality of distribution was assessed using the Shapiro-Wilk test. The serum levels of 
zinc and copper zinc ratios were normally distributed, but the serum level of copper did 
not have a normal distribution. Values are expressed as a mean with standard deviations 
for zinc and copper zinc ratio and median for copper levels. 
 
Comparisons were made using students‟ t-test for zinc and copper zinc ratios and 
Wilcoxon rank-sum test for zinc levels.  Comparisons were done between early stage 
NSCLC (stage II patients) and advanced stage NSCLC (stage III and IV patients).  
24 
 
Corresponding p-values were calculated to test for statistical significance at the 5% 
level. Data analysis was done using STATA version 10 statistical software (StataCorp, 
2008, Texas, USA).  
 
Ethical Clearance 
 
Ethical clearance was obtained from the University of Witwatersrand Committee                                           
for Research on Human Subjects (Medical) for permission to carry out this study   
(Protocol number PROTOCOL M02-10-33). See Appendix 1 and Appendix 2. 
 
Written consent was obtained from all patients who participated in this study (see 
Appendix 3).  
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CHAPTER FOUR: RESULTS 
 
Clinical Endpoints 
 
Relevant clinical histories, e.g. smoking history (active and passive), family history of 
cancer or lung cancer and employment history, were not specifically evaluated in this 
study. However, such data could provide useful information in a future, expanded, 
prospective study. 
 
Demographic Characteristics 
 
Table 1: Demographic characteristics of study participants 
 
Variable N= 34 Frequency (%) 
Age in years  (mean=61.1, std= 8.50) 
   40-50 3 (8.82) 
   50-60 9 (26.47) 
   60-70 17 (50.00) 
   >70 5 (14.7) 
Gender  
   Female 9 (26.5) 
   Male 25 (73.5) 
Race  
   Black 26 (76.5) 
   White 8 (23.5) 
 
A total of thirty-four patients participated in this study and males (73.5 %; 25) 
accounted for the majority.  The mean age of patients was 61.1 years (standard 
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deviation = 8.50 years).   Table 1 shows the demographic pattern, with 17 patients 
(50%) belonging to 60-70 year age group. More than three-quarters of the patients were 
Blacks (26) and the rest were Whites (8). There were no patients of Asian/Indian and 
Coloured (mixed race) origin. 
 
Figure 1: Distribution of participants by gender (males 25; females 9) 
 
 
 
Figure 1 shows the gender distribution of the 34 patients: 25 patients are male (74%); 9 
patients were female (26%) 
 
Data analysis was done using STATA version 10 statistical software (StataCorp, 2008, 
Texas, USA).  
 
 
 
Male
Female
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Cancer Stage Analysis 
 
Sixteen patients (47%) had Stage IV disease, while 14 (41.2%) and 4 (11.8%) were 
grouped into stage III and stage II respectively.  
 
In this study, patients aged 60–70 years were in the majority at all stages of NSCLC. 
Patients aged 50-60 years were the next most affected group for late stage NSCLC 
(stage III and IV); patients more than 70 years old were the third most affected group 
for early stage NSCLC (stage II). (See Table 2). 
 
There were more cases of NSCLC among males than females at all the stages of 
NSCLC. There is a male to female ratio of 3:1 (stage II) and 7:1 (stage IV). There was a 
more equal number of cases of male and female cases (8 vs. 6) at stage III. 
 
More Black patients had NSCLC in the late stage than White patients. There were no 
cases of stage II NSCLC among Black patients. 
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Table 2: Demographic characteristics of study participants by cancer stage 
 
 Stage II 
Frequency (%) 
Stage III 
Frequency (%) 
Stage IV 
Frequency (%) 
Age (years) 
   40-50 
 
0 (0) 
 
2 (14.29) 
 
1 (6.25) 
   50-60 0 (0) 3 (21.43) 6 (37.50) 
   60-70 3 (75.00) 7 (50.00) 7 (43.75) 
   >70 1 (25.00) 2 (14.29) 2 (12.50) 
Gender 
   Male 
 
3 (75.00) 
 
8 (57.14) 
 
14 (87.50) 
   Female 1 (25.00) 6 (42.86) 2 (12.50) 
Race 
   Black 
 
0 (0) 
 
12 (85.71) 
 
14 (87.50) 
   White 4 (100) 2 (14.29) 2 (12.50) 
 
Data analysis was done using STATA version 10 statistical software (StataCorp, 2008, 
Texas, USA).  
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Serum levels of Copper, Zinc and the Copper Zinc Ratio  
 
Figure 2-6 illustrate the overall levels of the above-mentioned trace elements and their 
ratio, as well as individual elements and their ratio vs. stage. 
 
Figure 2: The mean serum copper, zinc and copper zinc ratios of all 34 
participants. 
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Figure 3: Participants’ serum level of copper by NSCLC stage 
 
 
 
 
Mean SCL at different stages of NSCLC were 0.66mg/L, 0.74mg/L and 0.76mg/L for 
stage II, III and IV patients respectively.   
 
Data analysis was done using STATA version 10 statistical software (StataCorp, 2008, 
Texas, USA).  
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Figure 4: Participants’ serum level of zinc by NSCLC stage 
 
 
Mean serum zinc levels (SZL) at different stages of NSCLC were 0.70mg/L, 0.63mg /L 
and 0.62mg/L for stage II, III and IV patients respectively. 
 
Figure 5: Participants’ serum level of copper zinc ratio by NSCLC stage 
 
       
Copper zinc ratios at different stages of NSCLC were 0.995, 1.308 and 1.441 for stage 
II, III and IV patients respectively. 
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Figure 6: Combined copper, zinc levels and copper zinc ratio vs. stage in NSCLC 
 
 
 
 
 
 
 
 
 
Data analysis was done using STATA version 10 statistical software (StataCorp, 2008, 
Texas, USA).  
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
 
In this study, the data confirms previous reports of decreased SZL and elevated SCL in 
patients with NSCLC,
 28, 33, 41
 and provides useful local demographic information. 
 
5.1   Demographics 
 
Demographic findings show some correlation with established trends in the literature. 
10, 
11
 We know that lung cancer predominates in males and this is reflected in the study, 
with 71% of patients being male.
10, 11
 It is also in keeping with lung cancer accounting 
for a greater percentage of total cancers in males.  
 
The ratio of males to females (7:1) is at its highest in stage IV disease, which reflects 
later presentation in male patients. The aetiology of lung cancer is, to a large extent, 
associated with socio-economic factors, rather than phenotypical or genotypical factors, 
as reflected by the exaggerated proportion of males in this study.
51, 52, 53
 It also suggests 
that access to tertiary health care facilities still has a patriarchal bias in South African 
society.
51, 52, 53 
 
Advanced age at presentation is a marker of NSCLC. This is in keeping with its most 
common aetiology of accumulated and persistent mutations that are secondary to 
smoking. This study shows peak incidence in the 7
th
 decade, with a significant 
proportion in the 6
th
 and 8
th
 decades. This age distribution largely mimics data from 
Western studies, which is contrary to the usual finding of earlier age at presentation that 
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is commonly found at South African state institutions. A possible reason for this is that 
all patients were HIV negative, which alludes to a higher baseline medical and socio-
economic level in the South African context.
51, 52  
This participant sample would closer 
resemble a sample, using similar criteria, in a Western context. This finding also reflects 
the inadequate screening and therapeutic interventions for lung cancer even in resource-
rich environment.
6-11
 
 
Racial demographics closely resembled population statistics, though it should be noted 
that only White patients presented with early stage lung cancer. This is in keeping with 
the findings of American studies and is probably attributable to socio-economic factors,
 
10, 11
 rather than to genetic factors. In the South African context, this variable could be 
studied more accurately in a co-operative study between a private and public health 
facility, although its relevance is declining over time.
52, 53
 
 
5.2  Serum Copper and Zinc Levels in all Participants 
 
In this study, the mean serum level for copper measured in all 34 patients was 0.81 
mg/L (mean in healthy individuals 1.17mg/L).
41
 The mean serum copper was 
statistically lower than the reference mean serum level in healthy individuals (P<0.001). 
 
These results are contrary to findings from previous studies, which reported a higher 
serum level of copper in cancer patients when compared to healthy individuals .
41, 44 
One of the conclusions of these studies was the
 
role of serum copper as an acute phase 
marker.
41, 44
 This result should be interpreted with caution as this study did not have 
controls that would have made for a more reliable and accurate comparison.   It should 
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also be noted that the general condition of patients presenting at a South African state 
hospital oncology department would represent a low overall state of health and 
immunity baseline when compared to population samples in other studies.
52, 53
 The 
proportion of patients with early stage disease (11.8%) was also disproportionately low. 
 
The mean SZL in all patients was 0.63 mg/L (the mean in healthy individuals is 
0.94mg/L).
 39
 The mean serum zinc was statistically lower than the reference mean 
serum level in healthy individuals (P<0.001). The lower serum zinc level seen in this 
study correlates with other studies that compared SZL in patients with malignant 
conditions with serum levels in healthy individuals or individuals with benign 
conditions.
25, 41, 44
 The reduced serum level of zinc observed in patients with NSCLC 
may have led to the loss of the DNA and RNA stabilization function of zinc, thereby 
increasing the risk of developing lung cancer. This finding highlights the protective 
(anticarcinogenic) role of zinc. A diminished serum level of zinc might be a marker for 
the development of NSCLC. 
 
5.3 Serum Copper, Zinc and Copper Zinc Ratio by NSCLC Stage 
 
Table 3: Serum level of Copper, Zinc and Copper Zinc ratio by NSCLC stage among 
study participants 
 Stage II Stage III Stage IV 
  * Copper (mg/L) 0.66 (0.18) 0.74 (0.22) 0.76 (0.42) 
 ** Zinc (mg/L) 0.70 (0.067) 0.63 (0.072) 0.62 (0.09) 
 ** Copper Zinc ratio 0.99 (0.24) 1.31 (0.43) 1.44 (0.55) 
* Median (inter-quartile range) 
** Mean (standard deviation) 
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Although the serum level of copper demonstrated an increasing pattern with advancing 
stage of NSCLC in this study, this trend was not statistically significant. This is 
illustrated by the fact that patients with early stage NSCLC (stage II) had a mean level 
of 0.66mg/L, compared to  patients with late stage NSCLC (stage III and IV), who had a 
mean level of 0.75 mg/L (P=0.199). 
 
Similar studies reported elevated serum levels of copper in neoplastic conditions (when 
compared to a healthy control) and an increasing level of copper with advancing lung 
cancer.
25, 29
 In this study, the serum zinc level was shown to decline in patients with 
advancing stages of NSCLC. The decreasing serum levels of zinc with advancing stages 
of lung cancer in this study were not statistically significant; this was probably 
attributable to the small sample size. Patients with early stage NSCLC have a higher  
SZL when compared to patients with late stage NSCLC - 0.70mg/L mean stage II  
versus 0.62 mg/L mean stage III & IV, P=0.0897. 
 
Previous studies have reported statistically significant decreasing levels with advancing 
lung cancer .
25, 40
 These findings suggest a prognostic significance of declining SZLs. 
 
Copper zinc (Cu/Zn) ratio is considered to be a better discriminator than serum copper 
or SZL alone in the diagnosis and prognosis of malignancies.
25, 35
 As a diagnostic tool 
with 1.72 as a cut-off value, when comparing controls and lung cancer patients, copper 
zinc ratio had: a sensitivity of 89%, specificity of 84%, positive predictive value of 
78%, and a negative predictive value of 92%.
24
 Patients‟ eligibility for curative 
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resection and survival were also shown to be better in cancer patients with lower copper 
zinc ratios .
25
  
 
Even though the difference in copper zinc ratios in advanced NSCLC were not 
significantly different from early stage NSCLC, the mean value was higher in advanced 
NSCLC in this study, with 0.995, 1.308, 1.441 for stage II, III and IV patients 
respectively and a definite trend of an increasing ratio with progressive disease. This 
suggests that the copper zinc ratio could be used as a prognostic marker in NSCLC. 
Sensitivity, specificity, positive and negative predicative values for this study could not 
be calculated; this was because there was no control arm. 
 
Further studies in the South African population may be needed to provide evidence in 
support of these findings, which have elaborated the diagnostic and prognostic values of 
SCL and SZL and the copper zinc (Cu/Zn) ratio in cancer patients.
24, 32, 37
 
 
To conclude, the routine use of SCL, SZL and Cu/Zn ratios cannot be advocated as a 
tumour marker and prognostic variable for NSCLC as a result of this study. Further 
studies however, with a larger sample size, could demonstrate the role of the copper to 
zinc ratio as a cost-effective staging tool in NSCLC. 
 
Limitations 
 
1) The non-inclusion of a comparison group of patients (a healthy control group) 
from the same population as the NSCLC patients in this study limits the 
correlation and comparison of the findings with other studies of a similar nature. 
38 
 
The sample size (34 patients) was also relatively small when compared to other 
trials and the protocol of the trial limited data collection to a period of one 
calendar year (12 months). These factors were a result of logistic and funding 
limitations. 
2) The staging system used was AJCC 2002, which was the standard at the time. 
There has subsequently been a newer staging system (AJCC 2009), and caution is 
required when interpreting the data using the new system to prevent the effect of 
„stage migration‟. The author is, however, not aware of any similar or related 
study using the newer staging system. 
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